Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410647 | 0.89 | ROCK2 (0.64) | MAOBNAMPTHTR2CROCK2ROCK1 | |
| SCHEMBL5441326 | 0.87 | MAOB (0.79) | MAOBNR1H4NAMPTROCK2METTL3 | |
| SCHEMBL5412553 | 0.85 | MAOB (0.67) | MAOBEPHX2NR1H4ROCK2ALDH1A1 | |
| SCHEMBL5412689 | 0.85 | MAOB (0.67) | MAOBEPHX2NAMPTROCK2CYP2C9 | |
| SCHEMBL5405835 | 0.84 | MAOB (0.68) | MAOBNAMPTROCK2CYP2C9SMN1; SMN2 | |
| SCHEMBL5413102 | 0.84 | MAOB (0.71) | MAOBNAMPTROCK2METTL3MAPK1 | |
| SCHEMBL5409324 | 0.83 | MAOB (0.72) | MAOBEPHX2NAMPTROCK2METTL3 | |
| SCHEMBL5417278 | 0.82 | MAOB (0.71) | MAOBNAMPTROCK2METTL3MAPK1 | |
| SCHEMBL5406113 | 0.82 | MAOB (0.71) | MAOBNAMPTROCK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5179231 | 0.81 | MAOB (0.70) | MAOBNR1H4NAMPTROCK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558992-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO Pharmaceutical Co., Ltd. (JP) | 2019-10-30 | — | — | EP | claimed |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | claimed |
| WO-2018110669-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | WO | claimed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| EP-3558992-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO Pharmaceutical Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| WO-2018110669-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | WO | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | MAOB 2134/4885EPHX2 2514/4885NR1H4 2697/4885 |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | MAOB 2134/4885EPHX2 2514/4885NR1H4 2697/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | MAOB 2025/4885EPHX2 1010/4885NR1H4 1310/4885 |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | KCNJ11, KCNJ1, KCNJ8 | MAOB 2134/4885EPHX2 2514/4885NR1H4 2697/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | MAOB 2134/4885EPHX2 2514/4885NR1H4 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.